Trial Profile
Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary) ; Pembrolizumab (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PLANET
- 01 Sep 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Jun 2022.
- 01 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.